V Square Quantitative Management LLC Makes New $613,000 Investment in Quest Diagnostics Incorporated $DGX

11 Apr 2026, 11:52 by Danessa Lincoln · The Markets Daily

V Square Quantitative Management LLC acquired a new position in shares of Quest Diagnostics Incorporated (NYSE:DGX – Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 3,534 shares of the medical research company’s stock, valued at approximately $613,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of DGX. Perigon Wealth Management LLC lifted its stake in shares of Quest Diagnostics by 4.5% in the third quarter. Perigon Wealth Management LLC now owns 1,275 shares of the medical research company’s stock worth $243,000 after acquiring an additional 55 shares in the last quarter. Independent Advisor Alliance lifted its stake in shares of Quest Diagnostics by 1.4% in the third quarter. Independent Advisor Alliance now owns 4,232 shares of the medical research company’s stock worth $807,000 after acquiring an additional 59 shares in the last quarter. True North Advisors LLC lifted its stake in shares of Quest Diagnostics by 4.1% in the third quarter. True North Advisors LLC now owns 1,554 shares of the medical research company’s stock worth $296,000 after acquiring an additional 61 shares in the last quarter. Ossiam lifted its stake in shares of Quest Diagnostics by 6.1% in the third quarter. Ossiam now owns 1,059 shares of the medical research company’s stock worth $202,000 after acquiring an additional 61 shares in the last quarter. Finally, OLD Second National Bank of Aurora lifted its stake in shares of Quest Diagnostics by 14.9% in the third quarter. OLD Second National Bank of Aurora now owns 517 shares of the medical research company’s stock worth $99,000 after acquiring an additional 67 shares in the last quarter. Institutional investors and hedge funds own 88.06% of the company’s stock.

Insider Buying and Selling

In other news, SVP Karthik Kuppusamy sold 2,628 shares of the company’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $204.86, for a total transaction of $538,372.08. Following the completion of the transaction, the senior vice president directly owned 13,441 shares of the company’s stock, valued at approximately $2,753,523.26. This represents a 16.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Michael E. Prevoznik sold 3,878 shares of the company’s stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $206.21, for a total value of $799,682.38. Following the transaction, the senior vice president directly owned 37,557 shares of the company’s stock, valued at $7,744,628.97. This trade represents a 9.36% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 24,083 shares of company stock valued at $4,945,262 over the last three months. 8.16% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research firms recently commented on DGX. Evercore set a $210.00 price target on Quest Diagnostics in a research note on Wednesday. Mizuho boosted their price target on Quest Diagnostics from $210.00 to $235.00 and gave the stock an “outperform” rating in a research note on Thursday, February 12th. Wall Street Zen cut Quest Diagnostics from a “buy” rating to a “hold” rating in a research note on Sunday, March 15th. Truist Financial boosted their price target on Quest Diagnostics from $205.00 to $220.00 and gave the stock a “hold” rating in a research note on Wednesday, February 11th. Finally, UBS Group boosted their price target on Quest Diagnostics from $190.00 to $210.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 11th. Seven research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $210.69.

Read Our Latest Research Report on Quest Diagnostics

Quest Diagnostics Stock Down 3.1%

Shares of Quest Diagnostics stock opened at $191.62 on Friday. The firm has a market cap of $21.21 billion, a P/E ratio of 21.90, a P/E/G ratio of 2.55 and a beta of 0.66. The business has a 50-day moving average price of $199.97 and a 200 day moving average price of $188.50. Quest Diagnostics Incorporated has a fifty-two week low of $160.02 and a fifty-two week high of $213.50. The company has a quick ratio of 0.96, a current ratio of 1.04 and a debt-to-equity ratio of 0.72.

Quest Diagnostics (NYSE:DGX – Get Free Report) last posted its earnings results on Tuesday, February 10th. The medical research company reported $2.42 EPS for the quarter, beating the consensus estimate of $2.35 by $0.07. The company had revenue of $2.81 billion during the quarter, compared to analyst estimates of $2.75 billion. Quest Diagnostics had a return on equity of 15.57% and a net margin of 8.99%.The business’s revenue was up 7.1% compared to the same quarter last year. During the same period in the prior year, the company earned $2.23 earnings per share. Quest Diagnostics has set its FY 2026 guidance at 9.45-9.650 EPS. On average, sell-side analysts forecast that Quest Diagnostics Incorporated will post 9.7 earnings per share for the current fiscal year.

Quest Diagnostics declared that its Board of Directors has initiated a share repurchase program on Tuesday, February 10th that allows the company to repurchase $1.00 billion in shares. This repurchase authorization allows the medical research company to repurchase up to 4.7% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.

Quest Diagnostics Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, April 20th. Stockholders of record on Monday, April 6th will be issued a dividend of $0.86 per share. This represents a $3.44 annualized dividend and a dividend yield of 1.8%. This is a boost from Quest Diagnostics’s previous quarterly dividend of $0.80. The ex-dividend date of this dividend is Monday, April 6th. Quest Diagnostics’s dividend payout ratio is currently 39.31%.

Quest Diagnostics Profile

(Free Report)

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.